Eli Lilly has announced that Verzenios – also known as abemaciclib – in combination with endocrine therapy, has been recommended by the National Institute for Health and Care Excellence (NICE). It is an adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer and specifically involves adults whose disease is at high risk of recurrence.
This positive recommendation means that Verzenios is now available for use across NHS England via interim funding by the Cancer Drugs Fund or until routine NHS baseline funding is in place. The news comes just four weeks after the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation in the UK…
